There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
No Announcements
It manufactures, markets, sells, and distributes pharmaceuticals in India, covering multiple therapies.
Revenue from Operations: Rs 6,409.15 crore; Profit: Rs 1,414.44 crore.
Digene, Cremaffin, Thyronorm, Udiliv, Duphaston, Vertin, Creon, Duphalac, Prothiaden, and others.
All Indian states and UTs, plus Sri Lanka, Nepal, Maldives, Bhutan.
Single segment—Pharmaceuticals.
Promoters hold 74.99% (Abbott Capital India Ltd., U.K., 50.45%); no subsidiaries or joint ventures.
